http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-580491-B
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_832999f230974e686160c11f3929678d |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D213-643 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D407-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D335-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C323-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C323-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C317-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C317-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C321-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D309-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-16 |
filingDate | 1997-03-05^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2004-03-21^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92bb7f9ff766e8b1b6f6ab5cc61d1d2e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f31ae742b20117db3f9d5c96e0cded7e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c120104dba9058d4ef9f4326f66cb422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e868e60682b9a48d64d826a012ea952 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34de6a1cfff71b0ec12ec7da198479f8 |
publicationDate | 2004-03-21^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | TW-580491-B |
titleOfInvention | Aryl-S(O)n-substituted hydroxamic acids, and their preparation and use |
abstract | Compounds of the formula, wherein: n is 0, 1 or 2; Y is hydroxy or XONH-, where X is hydrogen or lower alkyl; R1 is hydrogen or lower alkyl; R2 is hydrogen, lower alkyl, heteroalkyl, aryl, aralkyl, arylheteroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl, heteroarylheteroalkyl, heterocyclo, heterocylo-lower alkyl, heterocyclo-lower heteroalkyl or -NR6R7, wherein: R6 is hydrogen, lower alkyl, cycloalkyl or cycloalkylalkyl, aryl, heteroaryl and heteroaralkyl; R7 is hydrogen, lower alkyl, cycloalkyl or cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, -C(O)R8, -C(O)NR8R9, -SO2NR8R9, -SO2R10, aryloxycarbonyl, or alkoxycarbonyl; or R6 and R7 together with the nitrogen atom to which they are attached represent a heterocyclo group; wherein R8 and R9 are independently hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl or heteroalkyl; and R10 is lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heteroalkyl or heterocyclo; or R1 and R2 together with the carbon atom to which they are attached represent a cycloalkyl or heterocyclo group; R3 is hydrogen, lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heteroalkyl or lower alkoxy; R4 is hydrogen, lower alkyl, cycloalkyl or cycloalkylalkyl; or R2 and R3 together with the carbons to which they are attached represent a cycloalkyl or heterocyclo group; or R3 and R4 together with the carbon to which they are attached represent a cycloalkyl or heterocyclo group; and R5 is lower alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl; or pharmaceutically acceptable salts or esters thereof exhibit useful pharmacological properties, in particular for use as matrix metalloprotease inhibitors, particularly for interstitial collagenases. |
priorityDate | 1995-12-20^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 738 of 738.